Bayer

Three additional pharma companies released fourth-quarter and full-year 2021 financial results in March. (Figures exclude exchange rate and portfolio changes where applicable.)
 
Merck KGaA’s group net sales in the fourth quarter rose 9.9% to $5.7 billion, beating consensus estimates of $5.6 billion. The German company attributed the growth to its “Big 3” businesses—the process solutions business of its life sciences segment, new healthcare products, and semiconductor solutions—…

Bayer will sell its pest control business to private equity player Cinven for $2.6 billion, the companies announced last week. Reuters noted that Bayer is seeking to pare debt in the wake of its $63 billion Monstanto acquisition in 2018.

Mentions:

The state of the fight: 

A U.S. FDA advisory panel recommended booster shots of the J&J and Moderna vaccines for select groups.
  CureVac will abandon development of its first-generation mRNA-based vaccine candidate.
  Brii Bio has submitted its monoclonal antibody cocktail to the U.S. FDA for Emergency Use Authorization. Approved or authorized vaccines

 
WHO advisory group backs extra dose for immunocompromised: WHO’s Strategic Advisory Group of Experts (…

Bayer announced Tuesday that it is upping its investment to over $460 million for new manufacturing facilities for long-acting reversible contraceptives (LARCs) and hormonal intrauterine systems (IUS).

The company plans to build a new “state-of-the-art” plant in Costa Rica by 2024 and expand previously announced manufacturing in Finland by 2025.

As part of an earlier sustainability commitment, Bayer is aiming to increase access to modern contraception to 100 million women and…

Bayer announced last week that it is acquiring drug discovery start-up Vividion Therapeutics for $1.5 billion upfront and up to $500 million more in potential milestone payments.

According to the press release, Bayer will gain full rights to the San Diego-based biotech’s chemoproteomic platform, which identifies “previously unknown binding pockets in undruggable targets” to generate novel compounds for oncology and immunology.

Mentions:

Bayer announced last week that it is investing a total of $303 million to build a new pharmaceutical facility and modernize an existing plant, both in Finland.

The expansion will help Bayer meet its goal of providing 100 million women in low- and middle-income countries with access to family planning and modern contraception by the end of 2030, the press release said.

Seven leading pharma companies released first-quarter 2021 financial results in May, while one Japanese firm reported full-year 2020 results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)
 
Leading the pack, first-quarter sales for South Korea’s newly public SK Bioscience soared 397% year-over-year to $101.1 million, as its Covid-19 vaccine CMO business started “making numbers in earnest” in supplying the AstraZeneca/…

Twelve leading pharma companies released fourth-quarter and full-year 2020 financial results in February. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, Gilead’s fourth-quarter revenue soared 26% over last year to $7.4 billion, beating consensus estimates by 4%. Veklury (remdesivir) drove the surge with $1.9 billion in quarterly sales: the antiviral now treats one in two hospitalized Covid-19 patients in the United States, according to the…

The state of the hunt:

Two versions of the AstraZeneca/Oxford vaccine secured EUL from the World Health Organization.
  J&J has applied for both WHO and EMA authorization for Janssen’s Covid-19 vaccine.
  The Pfizer/BioNTech shot remains stable at higher temperatures than previously believed.

 

Vaccines


Approved or authorized vaccines
 
Pfizer and BioNTech are testing their vaccine in pregnant women through a 4,000-participant…

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca’s vaccine…